Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

NCT05349617
Conditions
Chikungunya Virus
Interventions
CHIKV VLP/adjuvant, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
65 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Miami, Florida • Miami Lakes, Florida • St. Petersburg, Florida + 7 more
Conditions
Prevention of Chikungunya Virus Infection
Interventions
mRNA-1944, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Enrolling by invitation No phase listed Observational

Xpert® Tropical Fever Test on GeneXpert® Edge X System

NCT07520279
Conditions
Malaria Fever, Zika, Dengue Fever, Leptospirosis, Chikungunya Virus Infection
Interventions
Xpert Tropical Fever test
Diagnostic Test
Lead sponsor
Cepheid
Industry
Eligibility
14 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Chikungunya Virus Vaccine Trial in Healthy Adults

NCT01489358
Conditions
Viral Vaccines, Chikungunya Fever, Chikungunya Virus Infection
Interventions
VRC-CHKVLP059-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chikungunya Virus Infection
Interventions
Biological Vaccine VLA1553
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Coral Gables, Florida • Fort Myers, Florida • Ponte Vedra, Florida + 9 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

NCT03992872
Conditions
Chikungunya
Interventions
Chikungunya
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Fort Deterick, Maryland • Silver Spring, Maryland
Conditions
Chikungunya Virus Infection
Interventions
VLA1553, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years and older
Enrollment
4,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
44
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 39 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of SAR440894 vs Placebo

NCT04441905
Conditions
Chikungunya Virus Infection
Interventions
Placebo, SAR440894
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Orlando, Florida • Durham, North Carolina • Austin, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of Measles Vectored Chikungungya Vaccine

NCT03028441
Conditions
Chikungunya Virus Infection
Interventions
Placebo, VRC-CHKVLP059-00-VP
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Iowa City, Iowa • Houston, Texas
Conditions
Chikungunya
Interventions
VLA1553
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Huntsville, Alabama • Peoria, Illinois
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

NCT05072080
Conditions
Chikungunya Virus
Interventions
CHIKV VLP/adjuvant, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years to 64 Years
Enrollment
3,258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
47
States / cities
Huntsville, Alabama • Mobile, Alabama • Tempe, Arizona + 42 more
Conditions
Zika Virus, Dengue Virus, Chikungunya Virus Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

NCT03483961
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP/unadjuvanted, CHIKV VLP/adjuvanted, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
445 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Lenexa, Kansas • Kansas City, Missouri • West Jordan, Utah
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP vaccine booster, Placebo booster
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
24
States / cities
Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans

NCT03641339
Conditions
Zika, Dengue, Malaria, Chikungunya, Leishmaniasis
Interventions
One vector feeding, Four vector feeding
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Trial of an Inactivated Chikungunya Virus Vaccine

NCT06669208
Conditions
Chikungunya Fever, Chikungunya Virus, Chikungunya
Interventions
HydroVax-005 CHIKV, Placebo
Biological · Other
Lead sponsor
Najit Technologies, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

NCT04838444
Conditions
Chikungunya Virus Infection
Interventions
VLA1553
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
10
States / cities
Phoenix, Arizona • Hallandale, Florida • Chicago, Illinois + 7 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

NCT03325075
Conditions
Chikungunya Virus
Interventions
VAL-181388, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rockville, Maryland
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

NCT07003984
Conditions
Chikungunya Virus
Interventions
CHIKV VLP vaccine, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
1 Year to 11 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
8
States / cities
Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Conditions
Chikungunya Virus
Interventions
CHIKV VLP, adjuvanted
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas